Boehringer Ingelheim's in-development injection for psoriasis outpaced Johnson & Johnson's ($JNJ) blockbuster Stelara in a Phase II trial, setting the table for late-stage development. The treatment, BI 655066, better cleared the scaly plaques associated with psoriasis compared with J&J's drug, Boehringer said, working faster and for longer. The company is now plotting multiple Phase III studies to flesh out the treatment's potential, planning to eventually compete on the fast-crowding market for next-generation psoriasis therapies. Release